Liangzhi Zhong and Lu Chen contributed equally to this work and should be considered co-first authors
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Despite recent advances in multimodal treatments, the prognosis of patients with glioblastoma multiforme (GBM) remains poor. The aim of this study was to evaluate the efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with temozolomide (TMZ) for the postoperative treatment of GBM.
From February 2012 to February 2018, 80 patients with newly diagnosed and histologically confirmed GBM in our institute were reviewed retrospectively. All patients underwent complete resection or partial resection surgery and then received hypofractionated SIB-IMRT with concomitant TMZ followed by adjuvant TMZ. A total dose of 64 Gy over 27 fractions was delivered to the gross tumor volume (GTV), clinical target volume 1 (CTV1) received 60 Gy over 27 fractions, and CTV2 received 54 Gy over 27 fractions. The progression-free survival (PFS) and overall survival (OS) rates and the toxicities were evaluated. Prognostic factors were analyzed using univariate and multivariate Cox models.
The median follow-up was 16 months (range, 5~72 months). The median PFS was 15 months, and the 1-, 2-, and 3-year PFS rates were 56.0, 27.6, and 19.5%, respectively. The median OS was 21 months, and the 1-, 2-, 3-, and 5-year OS rates were 77.6, 41.6, 32.8, and 13.4%, respectively. The toxicities were mild and acceptable. Age, KPS scores and the total number of TMZ cycles were significant factors influencing patient survival.
Moderately hypofractionated SIB-IMRT combined with TMZ is a feasible and safe treatment option with mild toxicity and good PFS and OS.
Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66. CrossRef
Chamberlain MC. Radiographic patterns of relapse in glioblastoma. J Neuro-Oncol. 2011;101(2):319–23. CrossRef
Dobelbower MC, Burnet Iii OL, Nordal RA, et al. Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. J Med Imaging Radiat Oncol. 2011;55(1):77–81. CrossRef
McDonald MW, Shu HK, Curran WJ Jr, et al. Pattern of failure after limited radiotherapy and temozolomide for glioblastoma. Int J Radiat Oncol Biol Phys. 2011;79(1):130–6. CrossRef
Minniti G, Amelio D, Amichetti M, et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol. 2010;97(3):377–81. CrossRef
Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst. 1993;85(9):704–10. CrossRef
Nakagawa K, Aoki Y, Fujimaki T, et al. High dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1998;40(5):1141–9. CrossRef
Wang JZ, Li XA. Impact of tumor repopulation on radiotherapy planning. Int J Radiat Oncol Biol Phys. 2005;61(1):220–7. CrossRef
Floyd NS, Woo SY, Teh BS, et al. Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2004;58(3):721–6. CrossRef
Iuchi T, Hatano K, Narita Y, et al. Hypofractionated highdose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT. Int J Radiat Oncol Biol Phys. 2006;64(5):1317–24. CrossRef
Suzuki M, Nakamatso K, Kanamori S, et al. Feasibility study of the simultaneous integrated boost (SIB) method for malignant gliomas using intensity-modulated radiotherapy (IMRT). Jpn J Clin Oncol. 2003;33(6):271–7. CrossRef
Cho KH, Kim JY, Lee SH, et al. Simultaneous integrated boost intensity-modulated radiotherapy in patients with highgrade gliomas. Int J Radiat Oncol Biol Phys. 2010;78(2):390–7. CrossRef
Panet-Raymond V, Souhami L, Roberge D, et al. Accelerated Hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant Temozolomide for patients with glioblastoma Multiforme: a safety and efficacy analysis. Int J Radiat Oncol Biol Phys. 2009;73(2):473–8. CrossRef
Chen C, Damek D, Gaspar LE, Waziri A, et al. Phase I trial of hypofractionated intensitymodulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011;81(4):1066–74. CrossRef
Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–72. CrossRef
Yoon SM, Kim JH, Kim SJ, et al. Hypofractionated intensity-modulated radiotherapy using simultaneous integrated boost technique with concurrent and adjuvant temozolomide for glioblastoma. Tumori. 2013;99(4):480–7. CrossRef
Sultanem K, Patrocinio H, Lambert C, et al. The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial. Int J Radiat Oncol Biol Phys. 2004;58(1):247–52. CrossRef
Mallick S, Kunhiparambath H, Gupta S, et al. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial). J Neuro-Oncol. 2018;140(1):75–82. CrossRef
Scoccianti S, Krengli M, Marrazzo L, et al. Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the brain study Group of the Italian Association of radiation oncology (AIRO). Radiol Med. 2018;123(1):48–62. CrossRef
Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190–8. CrossRef
Darefsky AS, King JT Jr, Dubrow R. Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of surveillance, epidemiology, and end results registries. Cancer. 2012;118(8):2163–72. CrossRef
Scoccianti S, Magrini SM, Ricardi U, et al. Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the central nervous system study Group of Airo (Italian Association of Radiation Oncology). Neurosurgery. 2010;67(2):446–58. CrossRef
Darlix A, Baumann C, Lorgis V, et al. Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma. Anticancer Res. 2013;33(8):3467–74. PubMed
Sherriff J, Tamangani J, Senthil L, et al. Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide. Br J Radiol. 2013;86(1022):20120414. CrossRef
McDonald MW, Shu HG, Curran WJ, Crocker IR. Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. Int J Radiat Oncol Biol Phys. 2011;79(1):130–6. CrossRef
Milano MT, Okunieff P, Donatello RS, et al. Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys. 2010;78(4):1147–55. CrossRef
Schiffer D. Neuropathology and imaging: the ways in which glioma spreads and varies in its histological aspect. In: Walker M.D.,Thomas D.G.T., editors. Biology of brain tumour. Boston: Springer; 1986. p. 163–72. CrossRef
- Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience
- BioMed Central
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II